OXB and VLTS agreement on MetXia

Oxford Biomedica (LSE:OXB) and PolyMasc (London, U.K.) will jointly develop an enhanced version of OXB's MetXia cancer therapeutic. PolyMasc will combine its PEGylation technology with OXB's MetXia, w...